ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease.

This study provides additional evidence that Aβ administration can induce depression- and anxiety-like symptoms in rodents, and suggests that KATP channel inhibitors may be a plausible therapeutic strategy for treating affective disorders in AD patients. PMID: 29307659 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29307659?dopt=Abstract

Source: Brain Research Bulletin - January 4, 2018 Category: Neurology Authors: Esmaeili MH, Bahari B, Salari AA Tags: Brain Res Bull Source Type: research